Profile data is unavailable for this security.
About the company
Akums Drugs and Pharmaceuticals Limited is an India-based pharmaceutical contract development and manufacturing company. It offers a comprehensive range of pharmaceutical products and services in India and overseas. It is focused on providing end-to-end product development and manufacturing solutions to its clients. Its segments include Contract Development and Manufacturing Operations (CDMO), Active Pharmaceutical Ingredient (API) and Branded and Generic formulations. CDMO segment includes the formulation research and development, preparation and regulatory filing of dossiers, manufacturing formulations on a contract basis, job work and testing services. API segment is engaged in the manufacture and sale of key starting materials, Intermediate and API products. Branded and Generic formulations segment is engaged in marketing and distribution of branded and generic pharmaceutical formulations. It has manufactured 4,146 commercialized formulations across over 60 dosage forms.
- Revenue in INR (TTM)--
- Net income in INR--
- Incorporated2004
- Employees7.39k
- LocationAkums Drugs and Pharmaceuticals LtdMangolpuri Ind. AreaPhase-I, Plot No. 131 to 133, Block-CNEW DELHI 110034IndiaIND
- Phone+91 1 147511000
- Fax+91 1 127023256
- Websitehttps://www.akums.in/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Orchid Pharma Ltd | 8.81bn | 1.12bn | 76.05bn | 872.00 | 65.51 | -- | 51.90 | 8.63 | 22.89 | 22.89 | 180.65 | -- | -- | -- | -- | 10,101,540.00 | -- | -0.9734 | -- | -1.40 | 40.67 | 40.74 | 12.78 | -2.40 | -- | 6.08 | -- | -- | 23.05 | 6.43 | 73.59 | 5.84 | 57.79 | -- |
| Shilpa Medicare Ltd | 11.84bn | 447.57m | 83.32bn | 931.00 | 170.57 | -- | 54.43 | 7.04 | 5.00 | 5.00 | 133.55 | -- | -- | -- | -- | 12,716,850.00 | -- | 2.84 | -- | 3.65 | 65.19 | 60.08 | 3.79 | 7.03 | -- | 1.56 | -- | 10.76 | 9.66 | 9.44 | 198.15 | -22.26 | -9.26 | -- |
| F D C Ltd | 20.45bn | 3.14bn | 83.75bn | 6.66k | 26.77 | -- | 23.55 | 4.10 | 19.21 | 19.21 | 124.56 | -- | -- | -- | -- | 3,070,786.00 | -- | 12.05 | -- | 13.73 | 65.55 | 61.54 | 15.37 | 15.85 | -- | 75.15 | -- | 1.09 | 8.92 | 12.24 | 57.30 | 12.45 | 16.93 | -- |
| Procter & Gamble Health Ltd | 11.60bn | 2.18bn | 92.46bn | 1.41k | 42.48 | -- | 37.83 | 7.97 | 131.11 | 131.11 | 698.31 | -- | -- | -- | -- | -- | -- | -- | -- | -- | 71.42 | -- | 18.77 | -- | -- | 441.58 | -- | -- | -6.37 | -- | -12.42 | -- | -- | -- |
| Blue Jet Healthcare Ltd | 7.22bn | 1.68bn | 94.15bn | 447.00 | 56.09 | 10.19 | 49.15 | 13.04 | 9.68 | 9.68 | 41.61 | 53.27 | 0.6732 | 1.97 | 3.46 | 16,149,080.00 | 15.66 | -- | 19.57 | -- | 55.65 | -- | 23.26 | -- | 2.51 | 131.95 | 0.0012 | -- | -1.30 | -- | 2.33 | -- | -- | -- |
| Sanofi Consumer Healthcare India Ltd | 8.01bn | 2.31bn | 113.01bn | -- | 48.98 | 61.22 | 48.23 | 14.11 | 100.17 | 100.17 | 347.67 | 80.15 | -- | -- | -- | -- | -- | -- | -- | -- | 71.64 | -- | 28.81 | -- | 2.27 | 3,260.00 | 0.0986 | -- | -- | -- | -- | -- | -- | -- |
| Akums Drugs and Pharmaceuticals Ltd | -100.00bn | -100.00bn | 125.32bn | 7.39k | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 14.32 | -- | -104.25 | -- | -- | -- |
| Glenmark Life Sciences Ltd | 22.05bn | 4.24bn | 134.31bn | 2.01k | 31.80 | 5.29 | 27.94 | 6.09 | 34.47 | 34.47 | 179.44 | 207.17 | 0.7304 | 1.46 | 2.79 | 10,947,850.00 | 14.03 | 18.28 | 16.69 | 29.99 | 54.92 | 53.40 | 19.21 | 20.23 | 3.03 | 380.55 | 0.0063 | 26.37 | 5.64 | 20.83 | 0.841 | 19.21 | 69.11 | -- |
| Marksans Pharma Ltd | 22.68bn | 3.34bn | 135.68bn | 2.00k | 40.61 | -- | 32.73 | 5.98 | 7.37 | 7.37 | 50.09 | -- | -- | -- | -- | 11,339,960.00 | -- | 14.62 | -- | 18.52 | 53.39 | 50.52 | 14.71 | 14.03 | -- | 32.19 | -- | 6.17 | 17.56 | 16.84 | 17.80 | 32.62 | 73.86 | 64.38 |
| Granules India Ltd | 44.78bn | 4.87bn | 141.66bn | 4.12k | 29.11 | 4.13 | 20.29 | 3.16 | 20.08 | 20.08 | 184.59 | 141.41 | 0.8372 | 1.36 | 5.14 | 10,863,290.00 | 9.11 | 10.68 | 14.05 | 16.18 | 59.39 | 48.83 | 10.88 | 11.82 | 0.7152 | 6.88 | 0.2425 | 8.96 | -0.123 | 14.61 | -21.54 | 11.38 | 6.38 | 8.45 |
| Strides Pharma Science Ltd | 44.10bn | 1.77bn | 142.50bn | 3.07k | 80.63 | 6.27 | 38.34 | 3.23 | 19.22 | 25.15 | 479.84 | 247.16 | 0.7155 | 1.50 | 3.57 | 14,389,290.00 | 2.79 | -1.68 | 5.43 | -2.97 | 60.19 | 51.39 | 3.91 | -3.36 | 0.6355 | 1.52 | 0.5103 | -- | 9.83 | 13.21 | 43.57 | -- | -18.52 | -3.58 |
| Sanofi India Ltd | 21.92bn | 3.60bn | 148.59bn | 2.17k | 41.26 | -- | 37.39 | 6.78 | 156.36 | 199.60 | 951.86 | -- | -- | -- | -- | 10,083,720.00 | -- | 22.42 | -- | 30.21 | 53.94 | 55.52 | 16.43 | 21.03 | -- | 348.40 | -- | 135.49 | 2.92 | 0.573 | -2.85 | 9.64 | -10.34 | 14.73 |
| Caplin Point Laboratories Ltd | 18.31bn | 4.94bn | 152.92bn | 859.00 | 31.08 | 6.01 | 27.32 | 8.35 | 64.73 | 64.73 | 240.10 | 334.54 | 0.6861 | 2.28 | 3.40 | 21,312,920.00 | 18.62 | 19.83 | 21.36 | 22.82 | 58.72 | 53.38 | 27.14 | 25.39 | 5.07 | 932.86 | 0.0009 | 9.06 | 15.50 | 21.17 | 21.48 | 20.95 | 17.47 | 17.84 |
| Neuland Laboratories Ltd. | 15.28bn | 2.80bn | 176.96bn | 1.65k | 63.27 | 12.75 | 51.50 | 11.58 | 217.98 | 217.98 | 1,191.20 | 1,081.52 | 0.847 | 2.14 | 4.85 | 9,273,565.00 | 15.50 | 9.25 | 20.03 | 12.71 | 52.14 | 47.81 | 18.30 | 11.99 | 1.40 | 31.56 | 0.0728 | 7.13 | 30.84 | 18.51 | 83.51 | 78.76 | 17.88 | 63.45 |
| Eris Lifesciences Ltd | 24.98bn | 3.48bn | 177.79bn | 3.08k | 51.08 | 6.41 | 28.54 | 7.12 | 25.57 | 25.57 | 183.35 | 203.74 | 0.4585 | 2.90 | 5.96 | 8,110,753.00 | 6.73 | 13.42 | 8.39 | 16.80 | 77.03 | 79.98 | 14.69 | 24.96 | 0.8599 | 3.41 | 0.4626 | -- | 19.23 | 15.39 | 2.57 | 6.15 | 27.72 | -- |
| Astrazeneca Pharma India Ltd | 13.88bn | 958.59m | 182.67bn | 940.00 | 190.56 | -- | 164.70 | 13.16 | 38.34 | 38.34 | 555.18 | -- | -- | -- | -- | 14,761,520.00 | -- | 11.78 | -- | 19.62 | 48.51 | 54.64 | 6.91 | 10.27 | -- | 121.25 | -- | 25.62 | 29.17 | 12.21 | 62.66 | 24.29 | -10.46 | -- |
Data as of Nov 08 2024. Currency figures normalised to Akums Drugs and Pharmaceuticals Ltd's reporting currency: Indian Rupee INR
7.63%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Capital Research & Management Co. (World Investors)as of 30 Sep 2024 | 4.17m | 2.65% |
| Franklin Templeton Asset Management (India) Pvt Ltd.as of 31 Oct 2024 | 2.79m | 1.77% |
| SBI Funds Management Ltd.as of 31 Oct 2024 | 909.79k | 0.58% |
| PGIM India Asset Management Pvt Ltd.as of 30 Sep 2024 | 887.56k | 0.56% |
| HSBC Global Asset Management (Hong Kong) Ltd.as of 30 Sep 2024 | 870.69k | 0.55% |
| Edelweiss Asset Management Ltd.as of 31 Oct 2024 | 721.95k | 0.46% |
| Tata Asset Management Pvt Ltd.as of 31 Oct 2024 | 469.15k | 0.30% |
| Aditya Birla Sun Life Amc Ltd. (Investment Management)as of 31 Oct 2024 | 453.16k | 0.29% |
| Bandhan AMC Ltd.as of 30 Sep 2024 | 377.09k | 0.24% |
| Fidelity Management & Research Co. LLCas of 30 Sep 2024 | 355.23k | 0.23% |
More ▼
Data from 30 Jun 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
